Interferon-based hepatitis C therapy in a safety net hospital: Access, efficacy, and safety

European Journal of Gastroenterology and Hepatology

Volumn 29, Issue 1, 2017, Pages 10-16

  Nordstrom, Eric M ^a   Keniston, Angela ^b   Baouchi, Fafa ^b   Martinez Camacho, Alvaro ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

Health services accessibility; Hepatitis C; Interferon; Poverty; Safety net providers

Indexed keywords

BOCEPREVIR; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; AGE; ANTIBODY DETECTION; ANTIVIRAL THERAPY; ARTICLE; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FIB 4 SCORE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAPID VIROLOGIC RESPONSE; RETROSPECTIVE STUDY; SAFETY NET HOSPITAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS LOAD; BLOOD; CHI SQUARE DISTRIBUTION; COLORADO; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HEALTH CARE DELIVERY; HEPACIVIRUS; IMMUNOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTOR; SOCIOECONOMICS; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; COLORADO; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; SAFETY-NET PROVIDERS; SOCIOECONOMIC FACTORS; SUSTAINED VIROLOGIC RESPONSE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84991491230     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000755     Document Type: Article

References (30)

1. Singal AK, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95:755-760.
2. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. Worldwide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015; 62:1190-1200.
3. World Health Organization. Hepatitis C [fact sheet]. 2015. Available At: http://www.who.int/mediacentre/factsheets/fs164/en/. [Accessed 15 March 2015].
4. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31:1090-1101.
5. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Towards a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology 2015; 62:1353-1363.
6. Larney S, Mahowald MK, Scharff N, Flanigan TP, Beckwith CG, Zaller ND. Epidemiology of hepatitis C virus in Pennsylvania state prisons, 2004-2012: limitations of 1945-1965 birth cohort screening in correctional settings. Am J Public Health 2014; 104:e69-e74.
7. Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis 2005; 41:177-186.
8. Tsui JI, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. Dig Dis Sci 2009; 54:2694-2698.
9. Beste LA, Ioannou GN. Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev 2015; 37:131-143.
10. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
11. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
12. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395-403.
13. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
14. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
15. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
16. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
17. Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41:474-481.
18. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
19. Feuerstadt P, Bunim AL, Garcia H, Karlitz JJ, Massoumi H, Thosani AJ, et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51: 1137-1143.
20. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163:215-223.
21. Saab S, Jimenez M, Fong T, Wu C, Bau S, Jamal Z, et al. Accessibility to oral antiviral therapy for patients with chronic hepatitis C in the United States. J Clin Transl Hepatol 2016; 4:76-82.
22. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144:1450.e2-1455.e2.
23. Backus LI, Belperio PS. Impact of sustained virologic response on all-cause mortality. Hepatology 2013; 58:1508-1510.
24. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158 (Pt 1):329-337.
25. Ell K, Katon W, Xie B, Lee PJ, Kapetanovic S, Guterman J, et al. Collaborative care management of major depression among low-income, predominantly Hispanic subjects with diabetes: a randomized controlled trial. Diabetes Care 2010; 33:706-713.
26. Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs 2013; 73:263-277.
27. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology 2015; 61:783-789.
28. Coyle C, Viner K, Hughes E, Kwakwa H, Zibbell JE, Vellozzi C, et al. Identification and linkage to care of HCV-infected persons in five health centers-Philadelphia, Pennsylvania, 2012-2014. MMWR Morb Mortal Wkly Rep 2015; 64:459-463.
29. Andriulli A, Di Marco V, Margaglione M, Ippolito AM, Fattovich G, Smedile A, et al. Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014; 60:16-21.
30. Boglione L, Cusato J, Cariti G, Di Perri G, D'Avolio A. Treatment opti-mization of naive HCV-1 patients using IL28B, RVR and fibrosis stage. Antiviral Res 2015; 116:45-47.